43 results on '"Kukreti V"'
Search Results
2. CLINICAL UTILITY OF INTERIM CT SCANS IN PATIENTS RECEIVING CHEMOIMMUNOTHERAPY FOR FIRST LINE TREATMENT OF FOLLICULAR LYMPHOMA
3. PROGNOSTIC FACTORS IN ELDERLY PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA ‐ A JOINT ANALYSIS OF TWO CLINICAL DATABASES
4. PROSPECTIVE VALIDATION OF RECIL RESPONSE CRITERIA: RESULTS OF OBINUTUZUMAB‐GDP AS SALVAGE PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANT IN AGGRESSIVE B CELL LYMPHOMA
5. FUNCTIONAL PREDICTORS OF CHEMOTHERAPY TOXICITY IN ELDERLY LYMPHOMA PATIENTS - A PROSPECTIVE PILOT STUDY
6. PS1376 LENALIDOMIDE MAINTENANCE POSITIVELY IMPACTS OUTCOMES IN MULTIPLE MYELOMA WITHOUT NEGATIVE IMPACTS IN RELAPSE: AN ANALYSIS OF REAL WORLD DATA FROM THE MYELOMA CANADA RESEARCH NETWORK NATIONAL DATABASE
7. EFFICIENCY AND SAFETY OF STEM CELL MOBILIZATION FOLLOWING GDP SALVAGE IN PATIENTS WITH RELAPSED OR REFRACTORY LYMPHOMA
8. Treatment outcomes for older patients with relapsed/refractory aggressive lymphoma receiving salvage chemotherapy and autologous stem cell transplantation are similar to younger patients: a subgroup analysis from the phase III CCTG LY.12 trial
9. Treatment and Outcomes for Primary Cutaneous Extramedullary Plasmacytoma: A Case Series
10. Outcomes in Stage I-II Diffuse Large B-Cell Lymphoma Presenting With Extradural Involvement at a Single Centre (1995-2010)
11. Long Term Cryopreserved Autologous Blood Stem Cells For Salvage Autologous Stem Cell Transplantation (ASCT) in Relapsed Multiple Myeloma (MM) Patients
12. A Phase 1/2 Trial of the Insulin Growth Factor 1 Receptor (IGF-1R) inhibitor, Linsitinib in Combination with Bortezomib (BTZ) and Dexamethasone (Dex) for the Treatment of Relapsed/Refractory Multiple Myeloma (MM)
13. Myeloma Canada Research Network (MCRN) 001 Trial with Intravenous (IV) Busulfan + Melphalan (BuMel) as Enhanced Conditioning, followed by Lenalidomide (Len) Maintenance in Newly Diagnosed Multiple Myeloma (MM) Patients (Pts): First Results of Minimal Residual Disease (MRD) and Hevylite(TM) Chain (HLC) Assays at Day 100 Post Autologous Stem Cell Transplant (ASCT)
14. Outcome of t(4;14) in Multiple Myeloma – Princess Margaret Cancer Centre Experience Over the Last 10 Years
15. A single centre retrospective analysis of the addition of clarithromycin (biaxin) to lenalidomide and dexamethasone (len-dex) during time of progressive disease in patients with multiple myeloma (MM)
16. A Retrospective Analysis at the Princess Margaret Cancer Centre of the Initial Therapy of AL Amyloidosis: CyBorD versus Other Regimens
17. Noninvasive diagnosis of actionable mutations by deep sequencing of circulating cell free DNA (cfDNA) in multiple myeloma (MM)
18. Wax Content of Crude Oil: A Function of Kinematic Viscosity and Pour Point
19. CyBorD induction therapy in clinical practice
20. Systemic Treatment Safety Symposium 2014: Oral Chemotherapy
21. Early relapse after single auto-SCT for multiple myeloma is a major predictor of survival in the era of novel agents
22. Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure
23. ABSTRACT 327
24. Toward Successful Migration to Computerized Physician Order Entry for Chemotherapy
25. Implementation of a pediatric rapid response team: Experience of the hospital for Sick Children in Toronto
26. 020 Best Practices and Performance Measures for Systemic Treatment Perscriber Order Entry Systems (STCPOE) in Chemotherapy Delivery
27. Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study
28. Pattern of Failure in Patients With Stage I-II Hodgkin Lymphoma Treated With CMT: Implications of Partial Nodal Region Coverage and the Need for Adjacent Uninvolved Nodal Region Coverage
29. A Single Institution Experience of Extranodal Natural Killer/T-cell Lymphoma of Nasal Type
30. Studies on Volatile Characteristics of Middle Distillates and Their Interdependency
31. 9219 POSTER Combined Modality Therapy for Stage l-ll Diffuse Large B-cell Lymphoma Provides Excellent Local Control and Clinical Outcome in the Rituximab Era
32. Positron Emission Tomography for Response Assessment of Lymphoma Patients Having Residual Abnormalities following Initial Treatment: The Impact on Clinical Management
33. 9236 Results of PX-171–003-A0, part 1 of an open-label, single-arm, phase 2 study of carfilzomib in patients with relapsed and refractory multiple myeloma
34. 9201 Tolerability profile of carfilzomib enables full-dose anti-tumor treatment for up to 12 months
35. PX-171–004, a multicenter phase II study of carfilzomib (CFZ) in patients with relapsed myeloma: An efficacy update
36. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial
37. A493 Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed Myeloma (MM) (PX-171-004)
38. A334 Bortezomib-Based Therapy Following Prior Lenalidomide + Dexamethasone in Relapsed Multiple Myeloma
39. A378 Phase II Study of Carfilzomib in Patients with Relapsed Myeloma (PX-171-004)
40. A333 Phase I/II Trial of Cyclophosphamide, Prednisone, and Lenalidomide for Relapsed and Refractory MM
41. A458 Retropective Comparison of Engraftment After First and Second Autotransplantations for Relapsed Myeloma
42. Efficacy of induction with cybord in newly diagnosed multiple myeloma
43. Synthesis and spectra of some new phthalein dyes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.